TOP TEN perturbations for P59665 (Homo sapiens)

Organism: Homo sapiens
Gene: P59665
Selected probe(set): 205033_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P59665 (205033_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)

Relative Expression (log2-ratio):-8.593984
Number of Samples:7 / 8
Experimental precursor-B-ALL study 7 (PDX; long-term; >10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis).
Control precursor-B-ALL study 7 (late relapse; >24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

precursor-B-ALL study 7 (PDX; short-term; <10wk) / precursor-B-ALL study 7 (early relapse; <24m)

Relative Expression (log2-ratio):-8.452557
Number of Samples:5 / 22
Experimental precursor-B-ALL study 7 (PDX; short-term; <10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia (B-ALL) generated in NOD/SCID mice with time to manifestation of leukemia (TTL) less than 10 weeks (short-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene,;remision at day 33; non-high risk group; early relapse group (relapse within 24 months from diagnosis).
Control precursor-B-ALL study 7 (early relapse; <24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse within 24 months after diagnosis (early relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):7.4607944
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-7.4025974
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-6.861533
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors.

MALT lymphoma study 1 / normal spleen tissue

Relative Expression (log2-ratio):-6.6070204
Number of Samples:8 / 6
Experimental MALT lymphoma study 1
Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-6.179409
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC?s of HIV-seronegative donors.

MALT lymphoma study 2 / normal spleen tissue

Relative Expression (log2-ratio):-6.0442
Number of Samples:6 / 6
Experimental MALT lymphoma study 2
Human t(11;18)-positive mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):5.473777
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

AML study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.4808607
Number of Samples:38 / 74
Experimental AML study 1 (t(11q23))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.